“…Most of the previously available hERG computational models are ligand-based but since these rely mainly on the existence of structural similarities between the tested drug candidate and previously reported known hERG blockers, these models have limited value in the frequent case of a novel drug structure (Aronov and Goldman, 2004;Coi et al, 2006;Du-Cuny et al, 2011;Ekins et al, 2002;Keseru, 2003;Song and Clark, 2006;Su et al, 2010;Yoshida and Niwa, 2006). Producing a reliable hERG ion channel structure-based model to directly test drug binding (Broccatelli et al, 2012;Du-Cuny et al, 2011) has therefore been of high priority but in the absence of a hERG crystal structure, this has been limited to creating homology models that have excluded a large portion of the hERG channel and which display very limited conformational flexibility (Boukharta et al, 2011;Di Martino et al, 2013;Farid et al, 2006;Osterberg and Aqvist, 2005).…”